| Institutional Variability in Testing for Actionable Genetic Alterations in Patients with Stage IIIB/C or IV NSCLC: Real-World Data from the Prospective, Multicenter CRISP Registry (AIO-TRK-0315) |
Althoff FC |
Sebastian M |
| Oncol Res Treat 48 (Suppl 2):199 |
Abstract |
2025 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| doi.org/10.1159/000548147 |
|
|
| 2078eP - Combined chemo-immunotherapy versus monoimmunotherapy in advanced high PD-L1-positive NSCLC: Real-world data analyzed with propensity scores technique from the German prospective multicentre registry study (CRISP) |
Metzenmacher M |
|
| Ann Oncol 36 (Suppl. 2):1171 |
Abstract |
2025 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| doi.org/10.1016/j.annonc.2025.08.2699 |
|
|
| 1876P - Effectiveness of maintenance therapy with pembrolizumab vs pemetrexed and pembrolizumab in advanced non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315) |
Heinzen S |
Sebastian M |
| Ann Oncol 36 (Suppl. 2):1079-80 |
Abstract |
2025 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| doi.org/10.1016/j.annonc.2025.08.2500 |
|
|
| 2011P Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV NSCLC: Real-world data from the prospective, multicenter CRISP registry (AIO-TRK-0315) |
Althoff F |
Sebastian M |
| Ann Oncol 36 (Suppl. 2):1145-6 |
Abstract |
2025 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| doi.org/10.1016/j.annonc.2025.08.2635 |
|
|
| 1841eP - Real-world treatment and outcome of patients with stage II-III NSCLC in Germany from 2018-24 (prospective German registry CRISP, AIO-TRK-0315) |
Eberhardt WEE |
Thomas M |
| Ann Oncol 36 (Suppl. 2):1060 |
Abstract |
2025 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| doi.org/10.1016/j.annonc.2025.08.2464 |
|
|
| 2247P - Growth differentiation factor 15 (GDF-15) in localized, non-metastatic pancreatic cancer treated with multiagent induction chemotherapy: A biomarker analysis from the randomized phase II NEOLAP-1 trial (AIO-PAK-0113) |
Kimmel B |
Kunzmann V |
| Ann Oncol 36 (Suppl. 2): 1245 |
Abstract |
2025 |
|
Pankreaskarzinom
|
NEOLAP |
AIO-PAK-0113 |
| doi.org/10.1016/j.annonc.2025.08.2864 |
|
|
| Corrigendum to "mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)": [ESMO Open 9 (2024) 103703]. |
Hofheinz R |
Gaiser T |
| ESMO Open (2):104095 |
Sonstige |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
AIO-KRK-0214 |
| doi.org/10.1016/j.esmoop.2024.104095 |
|
|
| 481P - The predictive role of neutrophil-to-lymphocyte ratio in patients with solid cancers treated with immune checkpoint inhibitors: A pooled analysis of seven clinical trials of the German AIO study group |
Dreikhausen L |
Ebert M |
| Ann Oncol 36 (Suppl1):S181-2 |
Abstract |
2025 |
| doi.org/10.1016/j.annonc.2025.05.498 |
|
|
| CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism |
Sinn M |
Riess H |
| Oncol Res Treat 48 (11):685-95 |
Vollpublikation |
2025 |
|
Supportive Therapie
|
CONKO-011 |
AIO-SUP-0115/ass |
| doi.org/10.1159/000545976 |
|
|
| Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415). |
Bozorgmehr F |
Rieken S |
| Clin Exp Metastasis 42(5):42 |
Vollpublikation |
2025 |
|
Thorakale Onkologie
|
FORCE |
AIO/YMO-TRK-0415 |
| doi.org/10.1007/s10585-025-10358-x |
|
|
